Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Diabetes Mellitus, Insulin-Dependent, 12 × eribulin × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 24 Triple Negative Breast Neoplasms 10 Sarcoma 5 Neoplasm Metastasis 5 Liposarcoma 3 Inflammatory Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Leiomyosarcoma 2 Carcinoma, Transitional Cell 2 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Refractory Solid Tumors 1 Recurrence 1 Ketosis 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 HR+HER2- Breast Cancer 1 HER2-negative Metastatic Breast Cancer 1 HER2-low Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Colorectal Neoplasms 1 Brest Cancer 1 Brain Neoplasms 1 Advanced Breast Cancer 1

Interventions

tremelimumab 4 lenvatinib 3 durvalumab 3 Nivolumab 3 Ipilimumab 2 spartalizumab 1 relatlimab 1 poly ICLC 1 pembrolizumab 1 balstilimab 1 Radiotherapy 1 Peptides 1 Opdualag 1 Capecitabine 1 Bevacizumab 1 Axitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡